Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAVEN phase 3 trial of brolucizumab versus aflibercept for macular edema secondary to central retinal vein occlusion
MOH_2019-06-04_006072Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in central retinal vein occlusion (CRVO) comparing Brolucizumab arm with Aflibercept arm (2 arms). Started May 2019; status: completed.
02
Drugs
brolucizumabaflibercept
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on MOH_2019-06-04_006072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-04_006072.